GS-US-334-1113 A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

NCT02510300

A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Associated Conditions

Infectious Disease

Principal Investigator

Sponsor

Gilead Sciences

The purpose of this study is to continue to follow the response that the body has after participating in a Gilead-sponsored HCV treatment study.

This study is currently enrolling.